Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies
Authors' conclusion
CARS1 is the dominant cognate ARS autoantigen of the newly discovered anti-Ly ASA specificity. Rare and common ASA specificities could be detected by both unbiased and targeted IP-MS.
Study context
- Population
- Individuals with features of antisynthetase syndrome (ASyS), with or without previously detected antisynthetase autoantibodies, plus disease and healthy controls
- Participants
- 5 / 12 / 4
- Comparison
- ASyS features without antisynthetase autoantibodies (ASAs) vs ASyS features with ASAs vs Healthy controls
- ASyS features without ASAsn = 5
- ASyS features with ASAsn = 12
- Healthy controlsn = 4reference
- Outcome
- Discovery and detection of ASAs by IP-MS
Methodological detailsunbiased IP-MS discovery, IP-western blot confirmation, targeted IP-MS assay development and validation
- Unbiased IP-MS discovery
- IP-western blot confirmation
- Targeted IP-MS assay development and validation
Main finding
As reported in the abstract
- Autoantibodies to cytoplasmic cysteinyl-tRNA-synthetase (CARS1) identified by IP-MS and confirmed by western blot as a new ASA specificity, anti-Ly, in a patient with ASyS features
- Rare ASAs (anti-OJ, anti-Zo, anti-KS) and common ASAs also identified by IP-MS
- Targeted IP-MS approach for ASA detection developed and validated (known ASAs n=16, disease controls n=20, healthy controls n=25)
Further findings
Targeted IP-MS in additional cohort with multiple ASyS features or isolated myositis without previously detected ASAs (n=26)
- One additional patient with anti-OJ autoantibodies identified that were missed by line and dot immunoassays
- 1
Original publication
Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies. Ann Rheum Dis. Published 26 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →